ONEPOINT Launches Next Generation Project Life Cycle Support with Planforge 22
28.2.2023 11:00:00 EET | Business Wire | Press release
ONEPOINT, a Gartner leader in adaptive project management and reporting, today launched its new Planforge platform — the successor to its hybrid PPM software ONEPOINT Projects. The first major release, Planforge 22, focuses on providing next-generation project life cycle support for agile and traditional projects and programs, including a new dynamic project closure process, modernized change requests, vastly enhanced standard reports, and support for RACI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005123/en/
Planforge 22 supports a new dynamic project closure, lessons learned, and more. (Graphic: Business Wire)
"Planforge is our next step in making hybrid PPM more accessible and powerful at the same time," said Gerald Aquila, founder and CEO of ONEPOINT. "By implementing best practices and lessons learned from hundreds of customer projects analyzed by leading PPM consultants, our software has distinctive built-in project management expertise that is unique in the market."
Dynamic Project Closure
Built around an always accessible project closure form, the new dynamic project closure process is the cornerstone of many practical enhancements to the new Planforge platform:
- 1–5-star ratings and comments for overall project success, each objective and KPI
- Post-project phase can be easily planned using to-dos
- Lessons learned can be added at any time
- Redesigned project closure PDF standard report is based on new capabilities
Lessons Learned
Besides playing an essential role in the new project closure process, lessons learned are real lightweight business objects that are fully reportable using Planforge's flexible report wizard.
"This is a major first step to preserving important project know-how and providing transparency and important learnings to all project stakeholders. Learning from past mistakes and applying successes to future projects is becoming a key success factor," stated Dieter Freismuth, CTO of ONEPOINT.
Modernized Change Requests
Another success factor is effective change request management. By completely redesigning the way change requests are entered and displayed in Planforge, ONEPOINT has managed to incorporate latest best practices while simplifying the user interface. ONEPOINT made change requests more dynamic by allowing project managers to delegate ownership and prioritize changes. Additionally, the Planforge platform now includes a built-in, customizable standard report for a change request.
RACI
Other enhancements include support for RACI, enabling project managers to improve their overview of team responsibilities for complex projects and programs.
Availability
Planforge is available for free for up to 4 users both as a cloud service and on-premises. ONEPOINT also provides different plans for extended connectivity, including a bidirectional integration to Atlassian's Jira. Sign up now at www.planforge.io.
About
ONEPOINT Projects empowers teams to make projects work. With its Planforge hybrid PPM software, ONEPOINT simplifies daily project work with a practical approach to project and portfolio management and enterprise agile planning. Recognized as a Gartner APMR leader, ONEPOINT builds on major standards such as IPMA, PMI, PRINCE2, and SAFe, enabling project-driven organizations to increase project and portfolio transparency, reduce time to market, and optimize resource utilization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005123/en/
Contact information
ONEPOINT Projects GmbH
Kerstin Gaar
press@onepoint-projects.com
www.planforge.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom